• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:尹利端,尹雷,卢宪文,王静,胡梦蝶,杨爱琳,吕康宁.竹菊百合复合物保护小鼠急性肺损伤的作用及网络药理学分析[J].药学研究,2025,44(7):661-668,689[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1964次   下载 842次 本文二维码信息
码上扫一扫!
竹菊百合复合物保护小鼠急性肺损伤的作用及网络药理学分析
尹利端1,尹雷1,卢宪文2,3,王静2,4,胡梦蝶2,3,杨爱琳4,吕康宁2,5
字体:加大+|默认|缩小-
(1.烟台新时代健康产业有限公司,山东 烟台 264001;2.中国科学院烟台海岸带研究所,山东 烟台 264003;3.山东中医药大学青岛中医药科学院,山东 青岛 266112;4.滨州医学院药学院,山东 烟台 264003;5.中国石油大学<华东>化学化工学院,山东 青岛 266580)
摘要:
目的 竹菊百合复合物主要由百合、淡竹叶、罗汉果和沙棘等成分组成。验证竹菊百合复合物对脂多糖(lipopolysaccharide, LPS)所致小鼠急性肺损伤(ALI)的肺保护效果并研究其作用的潜在机制。方法 将60只SPF级雄性C57BL/6小鼠随机分为对照组、模型组、地塞米松组和竹菊百合复合物低、中、高剂量组(117.1 mg/20 g/d、234.3 mg/20 g/d和468.5 mg/20 g/d)。药物干预组分别灌胃相应药物15 d后,使用LPS(5 mg·kg-1)建立ALI模型。48 h后分析小鼠肺水肿和炎性细胞浸润程度、肺组织和肺泡灌洗液(bronchoalveolar lavage fluid, BALF)中炎症因子和肺组织病理变化,通过网络药理学和分子对接方法进行机制探索和验证。结果 与模型组相比,竹菊百合复合物高剂量组可显著降低小鼠肺湿干重比(P<0.001)、BALF和肺组织中MCP-1、TNF-α、IL-6 和 IL-1β含量(均P<0.05),减少肺组织炎性细胞浸润(P<0.001),并明显缓解肺组织炎性病变,降低肺水肿水平。经网络药理学和分子对接分析,竹菊百合复合物有效成分与ESR1、AKT1、PTGS2和JUN 4个核心靶点具有较好结合稳定性。结论 竹菊百合复合物可能通过调节炎性因子的表达及可能至少调控ESR1、AKT1、PTGS2和JUN等靶点相关信号通路来减轻ALI。
关键词:  急性肺损伤  竹菊百合复合物  网络药理学  分子对接
DOI:10.13506/j.cnki.jpr.2025.07.006
基金项目:山东省重点研发计划项目(No.2021CXGC010510)
Protective effect of Zhujubaihe compound on acute lung injury in mice and its network pharmacological analysis
YIN Liduan1,YIN Lei1,LU Xianwen2,3,WANG Jing2,4,HU Mengdie2,3,YANG Ailin4,LYU Kangning2,5
(1. Yantai New Era Health Industry Co., Ltd., Yantai, 264001, China; 2. Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; 3. Qingdao Academy of Chinese Medical Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, 266112, China; 4. School of Pharmacy, Binzhou Medical University, Yantai, 264003, China; 5. College of Chemistry and Chemical Engineering, China University of Petroleum, Qingdao, 266540, China)
Abstract:
Objective Zhujubaihe compound is mainly composed of bulb of greenish lily, common lophatherum, grosvenor momordica fruit and fruit of seabuckthorn. The lung protective effect and potential mechanism of Zhujubaihe compound on acute lung injury (ALI) induced by lipopolysaccharide (LPS) in mice was investigated. Methods Sixty SPF-grade male C57BL/6 mice were randomly divided into a control group, a model group, a dexamethasone group, and a Zhujubaihe compound low, medium, and high dose group (117.1 mg/20 g/d, 234.3 mg/20 g/d, and 468.5 mg/20 g/d). The ALI model was induced in C57BL/6 mice through administration of LPS (5 mg/kg) following 15 days of oral administration of the respective drugs in the drug intervention groups. After 48 h, the degree of lung edema and inflammatory cell infiltration, inflammatory factors and lung histopathological changes in lung tissues and bronchoalveolar lavage fluid (BALF) were analyzed in mice. Potential mechanisms were explored and validated by network pharmacology and molecular docking methods. Results Compared with the model group, the high-dose group of Zhujubaihe compound significantly decreased the wet-dry weight ratio of the lungs (P < 0.001). In bronchoalveolar lavage fluid (BALF) and lung tissue, MCP-1, TNF-α, IL-6 and IL-1β content were significantly decreased (P<0.05). And significantly decreased the infiltration of inflammatory cells in the lung tissues (P<0.001), as well as significantly alleviated the inflammatory lesions of the lung tissues and reduced the level of pulmonary edema. After network pharmacology and molecular docking analysis, the active ingredients of Zhujubaihe compound have good binding stability with the four core targets of ESR1, AKT1, PTGS2 and JUN. Conclusion Zhujubaihe compound shows promise in alleviating ALI by regulating the expression of inflammatory factors and potentially modulating signaling pathways associated with ESR1, AKT1, PTGS2, and JUN.
Key words:  Acute lung injury  Zhujubaihe compound  Network pharmacology  Molecular docking
今日访问量:2643    总访问量:55339157
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司